Stem definition | Drug id | CAS RN |
---|---|---|
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives | 700 | 911-45-5 |
Dose | Unit | Route |
---|---|---|
9 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1.11 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 8 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.52 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 90 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 1, 1967 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 258.56 | 47.13 | 104 | 1321 | 120911 | 50482788 |
Ovarian hyperstimulation syndrome | 179.71 | 47.13 | 36 | 1389 | 3208 | 50600491 |
Abortion spontaneous | 162.57 | 47.13 | 56 | 1369 | 41716 | 50561983 |
Heterotopic pregnancy | 148.98 | 47.13 | 16 | 1409 | 3 | 50603696 |
Multiple pregnancy | 94.88 | 47.13 | 12 | 1413 | 46 | 50603653 |
Ectopic pregnancy | 88.92 | 47.13 | 19 | 1406 | 2308 | 50601391 |
Adnexal torsion | 70.26 | 47.13 | 11 | 1414 | 232 | 50603467 |
Gestational diabetes | 66.91 | 47.13 | 19 | 1406 | 7446 | 50596253 |
Retinopathy of prematurity | 59.65 | 47.13 | 10 | 1415 | 327 | 50603372 |
Foetal exposure during pregnancy | 56.06 | 47.13 | 23 | 1402 | 27336 | 50576363 |
Cleft lip | 54.66 | 47.13 | 8 | 1417 | 105 | 50603594 |
Twin pregnancy | 53.54 | 47.13 | 11 | 1414 | 1102 | 50602597 |
Maternal exposure during pregnancy | 52.35 | 47.13 | 40 | 1385 | 159738 | 50443961 |
Pregnancy | 51.02 | 47.13 | 22 | 1403 | 29555 | 50574144 |
Premature baby | 50.14 | 47.13 | 19 | 1406 | 18318 | 50585381 |
Neonatal respiratory distress syndrome | 49.07 | 47.13 | 12 | 1413 | 2642 | 50601057 |
Maternal exposure before pregnancy | 49.04 | 47.13 | 14 | 1411 | 5583 | 50598116 |
Abortion threatened | 48.44 | 47.13 | 9 | 1416 | 534 | 50603165 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Foetal exposure during pregnancy | 64.25 | 47.96 | 23 | 451 | 33844 | 29540209 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Ovarian hyperstimulation syndrome | 191.08 | 38.24 | 35 | 1227 | 2810 | 64494660 |
Heterotopic pregnancy | 154.82 | 38.24 | 16 | 1246 | 3 | 64497467 |
Exposure during pregnancy | 120.11 | 38.24 | 48 | 1214 | 77627 | 64419843 |
Abortion spontaneous | 115.23 | 38.24 | 35 | 1227 | 25108 | 64472362 |
Ectopic pregnancy | 103.37 | 38.24 | 19 | 1243 | 1545 | 64495925 |
Multiple pregnancy | 93.31 | 38.24 | 11 | 1251 | 32 | 64497438 |
Gestational diabetes | 74.10 | 38.24 | 18 | 1244 | 5572 | 64491898 |
Adnexal torsion | 68.76 | 38.24 | 10 | 1252 | 185 | 64497285 |
Twin pregnancy | 67.09 | 38.24 | 12 | 1250 | 835 | 64496635 |
Abortion threatened | 54.18 | 38.24 | 9 | 1253 | 404 | 64497066 |
Caesarean section | 48.60 | 38.24 | 15 | 1247 | 11259 | 64486211 |
Ruptured ectopic pregnancy | 47.80 | 38.24 | 8 | 1254 | 376 | 64497094 |
Maternal exposure during pregnancy | 47.13 | 38.24 | 27 | 1235 | 95857 | 64401613 |
Maternal exposure before pregnancy | 45.04 | 38.24 | 11 | 1251 | 3472 | 64493998 |
Testicular atrophy | 41.70 | 38.24 | 7 | 1255 | 335 | 64497135 |
Muscle mass | 40.38 | 38.24 | 7 | 1255 | 406 | 64497064 |
None
Source | Code | Description |
---|---|---|
ATC | G03GB02 | GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM GONADOTROPINS AND OTHER OVULATION STIMULANTS Ovulation stimulants, synthetic |
FDA MoA | N0000000168 | Selective Estrogen Receptor Modulators |
CHEBI has role | CHEBI:50837 | oestrogen antagonist |
CHEBI has role | CHEBI:50751 | anti-estrogenic drug |
MeSH PA | D004965 | Estrogen Antagonists |
MeSH PA | D020847 | Estrogen Receptor Modulators |
MeSH PA | D005300 | Fertility Agents, Female |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D012102 | Reproductive Control Agents |
MeSH PA | D020845 | Selective Estrogen Receptor Modulators |
FDA EPC | N0000175826 | Estrogen Agonist/Antagonist |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Female infertility | indication | 6738008 | |
Ovulation induction | indication | 61285001 | |
Male infertility | off-label use | 2904007 | DOID:12336 |
Oligozoospermia | off-label use | 88311004 | |
Diagonstic Test for Hypothalamic Pituitary Gonadal Axis | off-label use | ||
Corpus Luteum Insufficiency Syndrome | off-label use | ||
Ovarian Function Studies | off-label use | ||
Severe adrenal insufficiency | contraindication | 24867002 | |
Depressive disorder | contraindication | 35489007 | |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Thrombophlebitis | contraindication | 64156001 | DOID:3875 |
Intermenstrual bleeding - irregular | contraindication | 64996003 | |
Polycystic ovaries | contraindication | 69878008 | |
Cyst of ovary | contraindication | 79883001 | |
Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
Neoplasm of pituitary gland | contraindication | 127024001 | DOID:1785 |
Endometriosis | contraindication | 129103003 | |
Ovarian hyperstimulation syndrome | contraindication | 129635004 | DOID:5425 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Endometrial carcinoma | contraindication | 254878006 | DOID:2871 |
Pregnancy, function | contraindication | 289908002 | |
Lesion of brain | contraindication | 301766008 | |
Thromboembolic disorder | contraindication | 371039008 | |
Visual impairment | contraindication | 397540003 | |
Scotomata | contraindication | ||
Visual Disturbance of Seeing Spots | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.9 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Estrogen receptor | Nuclear hormone receptor | MODULATOR | Ki | 8.89 | DRUG MATRIX | CHEMBL | |||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.46 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 8.10 | CHEMBL | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.75 | WOMBAT-PK | |||||
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Enzyme | Ki | 9 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.47 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 6.07 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.03 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.06 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.18 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.71 | CHEMBL | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.14 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.35 | DRUG MATRIX | |||||
Histamine H1 receptor | GPCR | Ki | 5.19 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.41 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.89 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.36 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.64 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.90 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 5.37 | DRUG MATRIX | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.67 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 6.21 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 5 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.52 | DRUG MATRIX | |||||
Epidermal growth factor receptor | Kinase | IC50 | 5.98 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.60 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 5.78 | DRUG MATRIX | |||||
Substance-K receptor | GPCR | Ki | 5.82 | DRUG MATRIX | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 6.46 | DRUG MATRIX | |||||
Androgen receptor | Transcription factor | IC50 | 4.87 | CHEMBL | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 5.60 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 7.52 | DRUG MATRIX | |||||
C-8 sterol isomerase | Enzyme | Ki | 6.80 | CHEMBL |
ID | Source |
---|---|
4018616 | VUID |
N0000179535 | NUI |
D00962 | KEGG_DRUG |
50-41-9 | SECONDARY_CAS_RN |
142431 | RXNORM |
4018616 | VANDF |
4019686 | VANDF |
C0009008 | UMLSCUI |
CHEBI:3752 | CHEBI |
53Q | PDB_CHEM_ID |
CHEMBL2355051 | ChEMBL_ID |
CHEMBL3185958 | ChEMBL_ID |
DB00882 | DRUGBANK_ID |
4159 | IUPHAR_LIGAND_ID |
1548953 | PUBCHEM_CID |
362 | MMSL |
4475 | MMSL |
d00569 | MMSL |
002101 | NDDF |
004781 | NDDF |
30466001 | SNOMEDCT_US |
387166005 | SNOMEDCT_US |
387346007 | SNOMEDCT_US |
D002996 | MESH_DESCRIPTOR_UI |
1309 | INN_ID |
1HRS458QU2 | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Clomid | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0885 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-114 | TABLET | 50 mg | ORAL | ANDA | 18 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-701 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0677 | TABLET | 50 mg | ORAL | NDA authorized generic | 22 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0678 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0678 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3059 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
CLOMIPHENE CITRATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 61919-375 | TABLET | 50 mg | ORAL | ANDA | 10 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2165 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2165 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-5302 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-5302 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-9276 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-2638 | TABLET | 50 mg | ORAL | ANDA | 17 sections |
Clomiphene Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-4676 | TABLET | 50 mg | ORAL | ANDA | 17 sections |